Compare GE Aerospace (GE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs TransMedics Group Inc — how do they compare? GE Aerospace trades at $365.61 (market cap $379.05B), while TransMedics Group Inc trades at $87 (market cap $3.02B). The key difference: GE Aerospace is far larger — about 125.5× TransMedics Group Inc's market cap, and GE Aerospace pays a 0.51% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| GE | TMDX | |
|---|---|---|
Market Cap | $379.05B | $3.02B |
Sector | Industrials | Technology |
52-Week High | $381.22 | $150.42 |
52-Week Low | $265.93 | $61.99 |
Enterprise Value | $388.86B | $3.41B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $368.06, up 0.37% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with Q2 2026 EPS of $2.02 beating expectations and revenue growth accelerating to $45.86B in 2025. Recent defense contract wins and commercial engine demand fuel optimism, though elevated valuation metrics warrant caution.
Outlook remains positive with 68.6% analyst buy ratings and $414.11 consensus target suggesting 12.5% upside. Key risks include high debt levels and rich valuations, but strong order backlog and defense contracts provide growth catalysts. Earnings momentum and institutional support position GE for continued outperformance in aerospace sector.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
